(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of 113.91% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Ikena Oncology's revenue in 2024 is $3,848,000.On average, 1 Wall Street analysts forecast IKNA's revenue for 2024 to be $675,613,554, with the lowest IKNA revenue forecast at $675,613,554, and the highest IKNA revenue forecast at $675,613,554. On average, 1 Wall Street analysts forecast IKNA's revenue for 2025 to be $965,162,220, with the lowest IKNA revenue forecast at $965,162,220, and the highest IKNA revenue forecast at $965,162,220.
In 2026, IKNA is forecast to generate $1,930,324,440 in revenue, with the lowest revenue forecast at $1,930,324,440 and the highest revenue forecast at $1,930,324,440.